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Abstract
Huntington’s disease (HD) is a hereditary neurodegenerative disorder characterized by brain atrophy particularly in striatum
leading to personality changes, chorea and dementia. Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase in the
crossroad of many signaling pathways that is highly pleiotropic as it phosphorylates more than hundred substrates including
structural, metabolic, and signaling proteins. Increased GSK-3 activity is believed to contribute to the pathogenesis of
neurodegenerative diseases like Alzheimer’s disease and GSK-3 inhibitors have been postulated as therapeutic agents for
neurodegeneration. RegardingHD, GSK-3 inhibitors have shown beneﬁcial effects in cell and invertebrate animalmodels but no
evident efﬁcacy in mouse models. Intriguingly, those studies were performed without interrogating GSK-3 level and activity in
HD brain. Herewe aim to explore the level and also the enzymatic activity of GSK-3 in the striatum and other less affected brain
regions of HD patients and of the R6/1 mouse model to then elucidate the possible contribution of its alteration to HD
pathogenesis by geneticmanipulation inmice.We report a dramatic decrease inGSK-3 levels and activity in striatumand cortex
ofHDpatientswith similar results in themousemodel. Correction of theGSK-3 deﬁcit inHDmice, by combiningwith transgenic
mice with conditional GSK-3 expression, resulted in amelioration of their brain atrophy and behavioral motor and learning
deﬁcits. Thus, our results demonstrate that decreased brain GSK-3 contributes to HD neurological phenotype and open new
therapeutic opportunities based on increasing GSK-3 activity or attenuating the harmful consequences of its decrease.
Introduction
Huntington’s disease (HD) is an inherited neurodegenerative dis-
order characterized by motor, psychiatric and cognitive symp-
toms (1). The major site of neuronal loss is the striatum
although brain atrophy extents to other regions (1). HD is caused
by a CAG triplet expansion in exon 1 of the huntingtin (htt) gene
(2) leading to an expanded polyglutamine stretch in the mutant
protein. The exact mechanism by which expanded CAG mRNA
sequence and/or polyglutamine-induced neurodegeneration
remains unknown. However, N-terminal forms of mutant
huntingtin (mhtt) are known to accumulate in the cytoplasm
and interact with several proteins causing impairment of signal-
ing pathways (3).
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine
kinase expressed in all tissues, although levels aremore abundant
in the brain. There are two paralogs of this enzyme, GSK-3α and
GSK-3β, which are almost identical, particularly in their catalytic
domains (4), and that are regulated by multiple mechanisms
(5–7) including substrate priming, cellular trafﬁcking, incorpora-
tion into protein complexes like axin/APC, D2R/β-arrestin (8,9) or
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D2R/Disc1 (10) and post-translational modiﬁcations such as phos-
phorylation at anN-terminal serine residue (Ser 21/9 for α and β, re-
spectively) that renders the kinase inactive in some of its possible
functional scenarios (5). GSK-3 is a pleiotropic enzyme as it is able
to phosphorylate more than hundred proteins involved in func-
tions suchasmetabolism, cell structure, gene expression including
epigenetics, and apoptosis (5,6).
GSK-3 activity is tuned by self-activating mechanisms (5) and
it has been postulated that abnormally increased GSK-3 activity
contributes to the pathogenesis of neurodegenerative and psy-
chiatric diseases like Alzheimer’s disease (6,11) and bipolar dis-
order (12,13). Accordingly, the non-selective GSK-3 inhibitor
lithium is used as a therapy for bipolar disorder (14) and has
been explored in clinical trials for Alzheimer’s disease (15,16),
and selective GSK-3 inhibitors are under development for
possible therapeutic interventions (5,17–19).
Regarding HD, GSK-3 inhibition has been shown to protect
against polyglutamine-induced cell death and to reduce the
number of huntingtin inclusions in cell (20,21) and invertebrate
animal (22,23)models. However, therapeutic efﬁcacy of GSK-3 in-
hibitionwasnot evident in rodentmodels (24) as GSK-3 inhibitors
showed beneﬁcial effects only when combined with other drugs
(25,26) particularly those that stimulate autophagy, which may
counteract the decreased autophagy elicited by GSK-3 inhibition
(27). However, the main reason for GSK-3 inhibitors not showing
a clear beneﬁcial effect by themselves in HDmousemodels could
be that GSK-3 levels and activity might not be increased in HD. In
fact, we and others have previously found increased N-terminal
serine phosphorylation of GSK-3 in striatum and other brain re-
gions of various HD mouse models thus suggesting that GSK-3
activity, rather than increased, might be reduced in HD (28–30)
and, although no data are available regarding striatum of
postmortem human HD brain, decreased GSK-3β levels have re-
cently been reported in frontal cortex of HD brains (29). In line
with the notion that decreased striatal GSK-3 activity could
contribute to HD, transgenic mice with forebrain expression of
a dominant-negative form of GSK-3 show reduced GSK-3 activity
and increased neuronal apoptosis in the striatum and alsomotor
deﬁcits in striatal-dependent tasks, thus showing an HD-like
phenotype (31,32).
In the present study, we aim to explore the level and also the
enzymatic activity of GSK-3 in the striatum and other affected
brain regions of HD patients andmousemodels to then elucidate
the possible contribution of its alteration to HD pathogenesis by
genetic manipulation in mice.
Results
Decreased GSK-3 level and activity in HD brain
To investigate the status of GSK-3 in the brain of HD patients,
here we analyzed for the ﬁrst time the level of GSK-3 in striatum
of HD patients and non-affected individuals. By western blot, we
observed that levels of both GSK-3 isoforms were dramatically
decreased in the striatum of HD brains respect to control brains
(P = 0.028 for α and P = 0.045 for β). We also analyzed samples
from cortex and hippocampus and a decrease of both isoforms
was also observed in cortex (P = 0.006 for α and P = 0.01 for β)
while only a tendency to decrease was observed in hippocampus
(Fig. 1A). As shown in Supplementary Material, Figure S1A–C, no
obvious contribution of sex, age or postmortem interval (PMI) is
observed to these effects. Interestingly, these decreases in GSK-
3α and GSK-3β protein levels in striatum and cortex of HD brains
do not seem to be due to altered transcription of the GSK-3α and β
genes as quantitative RT-PCR analysis of RNA extracted from HD
brains revealed that the transcripts of GSK-3α or β are not dimin-
ished in the HD samples (Fig. 1B).
As a way to explore whether the observed decrease in GSK-3
protein levels would precede neurodegeneration rather than re-
ﬂecting a late consequence of the neuronal loss dysfunction,
we analyzed the samples with low Vonsattel grade separately.
As shown in Supplementary Material, Figure S1D, in this limited
number of low-grade HD postmortem brains (Grade 1, n = 1;
Grade 2, n = 3), the striatal decrease seems to happen even in
the Grade 1 case and the cortical decrease seems to manifest
from Grade 2 onwards. This suggests that the observed decrease
might predate neurodegeneration rather than just being conse-
quence of the neurodegeneration of the vulnerable cells and
preservation of the speared ones.
GSK-3 protein levels are not a direct indicator of GSK-3 activity
and, as mentioned, an indirect way to explore GSK-3 activity in
some of its possible functional scenarios is by analyzing the le-
vels of phosphorylation of GSK-3 at serine-9 for GSK-3β and at
serine-21 for GSK-3α. We thus performed western blot analysis
of the inhibitory N-terminal serine phosphorylation of GSK-3 in
control and HD samples. However, the previously reported (33)
instability of the epitope in human brain tissue associated with
postmortem interval, precluded conclusive results. Then, as a
direct indicator of activity,we performed an in vitroGSK-3 enzym-
atic activity assay on homogenates from striatum, cortex and
hippocampus of HD patients and controls using a pre-phos-
phorylated peptide as a well-characterized substrate of GSK-3.
In linewith the observed decrease in GSK-3 protein levels, we de-
tected a signiﬁcant decrease in GSK-3 activity in the striatum
(73.9%; P = 0.005) and cortex (56.5%; P = 0.001) of HD cases versus
controls while only a tendency was observed in hippocampus
(Fig. 1C). These results indicate that GSK-3 protein levels and
activity are decreased in the two most affected brain regions of
HD patients.
Decreased GSK-3 levels and activity in the R6/1 mouse
model of HD
We and others have previously found increased N-terminal ser-
ine phosphorylation of GSK-3 as indicator of reducedGSK-3 activ-
ity in selected regions of R6/1 mouse model of HD (28,29). To
further explore if the results obtained from human HD brain
can be recapitulated in this mouse model, we analyzed GSK-3 le-
vels, p-Ser-GSK-3 levels and activity in the striatum, cortex and
hippocampus of R6/1 mice at pre-symptomatic ages (4 and 8
weeks), at an early symptomatic age (3.5 months) and at a late
symptomatic age (7.5 months). Analysis of GSK-3 protein levels
by western blot showed a tendency to decreased GSK-3 level in
cortex of 8-week-old R6/1 mice respect WT mice (data not
shown) and the earliest signiﬁcant decreases were found in stri-
atum (P < 0.0001) and cortex (P = 0.006) of early symptomatic (3.5
months) R6/1 mice compared with WT animals (Fig. 2A and B).
Regarding the hippocampus, a signiﬁcant decrease in GSK-3
level is found only at late symptomatic stages of the R6/1 mice
(Fig. 2B). As observed in the brain of HD patients, this decrease
was not a consequence of diminished transcript levels as qRT-
PCR analysis revealed that transcript level of GSK-3α and β
genes is not signiﬁcantly altered (Fig. 2C).
As mentioned, an indirect way to explore GSK-3 activity in
some of its possible functional scenarios is by analyzing the le-
vels of phosphorylation at the N-terminal serine residues. In
good agreement with previous reports (28,29), we observed a sig-
niﬁcant increase in the levels of p-GSK-3 in: striatum (P = 0.013) of
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presymtomatic (8 weeks old) R6/1 mice (data not shown); in stri-
atum (P = 0.049), cortex (P = 0.005) and hippocampus (P = 0.00025)
of 3.5-month-old early symptomatic R6/1 mice (Fig. 2D); and in
striatum (P = 0.019), cortex (P = 0.002) and hippocampus (P = 0.009)
of 7.5-month-old late symptomatic R6/1mice comparedwithWT
mice (Fig. 2E). These ﬁndings were conﬁrmed by immunohisto-
chemistry in striatum and cortex of 3.5-month-old R6/1 mice
that show a signiﬁcant increase in the number of p-Ser-GSK-3α/
β-positive cells (Supplementary Material, Fig. S2A) and double
immunoﬂuorescence with astrocytic (GFAP) or neuronal (NeuN)
markers (Supplementary Material, Fig. S2B and C) revealed that
the cells with increased p-Ser-GSK-3α/β staining are neurons.
Together, the datawith the anti-p-Ser-GSK-3α/β antibody further
suggest decreased GSK-3 activity in the brain of R6/1 mice.
To conﬁrm that decreased total levels and increased p-GSK-3
indeed result in decreased activity, we performed the GSK-3 en-
zymatic activity assayonhomogenates fromstriatum, cortex and
hippocampus of R6/1 mice. The earliest signiﬁcant decrease in
GSK-3 activity was observed in striatum (23%; P = 0.002) of early
symptomatic (3.5 months old) R6/1 mice (Fig. 2H) compared
with WT and similar results (21.6%; P = 0.006) were observed in
late symptomatic (7.5 months old) R6/1 mice (Fig. 2I). A tendency
to decrease was also observed in cortex and hippocampus of 7.5-
month-old R6/1 mice (Fig. 2I). To try to explain why the decrease
in activity assay is restricted to the striatum, we decided to ana-
lyze also phosphorylation of GSK-3 at the Tyr216/279 residues
which is believed to correlate with activated GSK-3 (5). As
shown in Supplementary Material, Figure S3, p-Tyr279-GSK-3α
and p-Tyr216GSK-3β are signiﬁcantly decreased only in striatum
(P = 0.004 for α and P = 0.028 for β) of R6/1 mice while they are sig-
niﬁcantly increased in cortex (P = 0.015 for α and P = 0.025 for β)
and hippocampus (P = 0.015 for α and P = 0.012 for β) of R6/1
mice. This may be the reason why the decrease in enzymatic
activity assay only reaches signiﬁcance in striatum.
Generation of R6/1 mice with varying levels
of transgenic GSK-3
To test whether the observed decreased GSK-3 level and activity
in the brain of R6/1 mice contributes to their HD-like phenotype,
we decided to explore the consequences of modifying GSK-3 le-
vels by genetic manipulation. For this, we produced R6/1 mice
with varying levels of transgenic GSK-3 expression. We have pre-
viously generated the BitetO-β-Gal/GSK-3β transgenicmouse line
(34) that harbors a DNA construct with a GSK-3β sequence and, as
a reporter of gene expression, also a β-galactosidase sequence
with a nuclear localization signal. These two coding sequences
are under the control of the two CMV minimal promoters
Figure 1. Analysis GSK-3 levels and activity in striatum, cortex and hippocampus of HD patients. (A) Western blot detection of GSK-3α/β levels in homogenates from the
striatum, cortex and hippocampus of HD patients and controls (n = 8 for striatum, n = 11–10 for cortex and n = 4 for hippocampus; Student’s t-test, **P < 0.01, *P < 0.05).
(B) Quantitative RT-PCR analysis of GSK-3α and GSK-3β mRNA in striatum and cortex of HD and control samples (n = 5–7 for striatum and n = 9-8 for cortex; only
samples with RNA integrity number (RIN) >5 were included in the analysis). (C) In vitro GSK-3 activity assay performed in homogenates from the striatum, cortex and
hippocampus of HD patients and control subjects (n = 8 for striatum, n = 10 for cortex and n = 3–9 for hippocampus, Student’s t-test; **P < 0.01, *P < 0.05).
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(CMVmin) in the bidirectional tetO promoter (BitetO) (Fig. 3A).
These BitetO-β-Gal/GSK-3β mice show a modest expression of
the β-Gal reporter in brain areas such as the striatum, cortex or
hippocampus (Fig. 3B) and of transgenic GSK-3β mRNA (Fig. 3F)
and only those cells with high levels of the reporter β-Gal show
increased GSK-3 levels as evidenced by double β-Gal/GSK-3
immunoﬂuorescence (Fig. 3C). In previous characterizations
of these mice, no obvious behavioral phenotypes have been
observed (35,36). Here, we will refer to these animals as
LowTgGSK-3 mice. Besides, we have also previously reported
that when LowTgGSK-3mice are combinedwithmice expressing
the tetracycline transactivator (tTA, also known as Tet-Off) under
control of the forebrain neuronal promoter CamKII (CamKII-tTA
mice), the resulting double transgenic mice CamKII-tTA +
BitetO-β-Gal/GSK-3β (Fig. 3D) show robust neuronal expression
in all forebrain regions such as the striatum, cortex and hippo-
campus (Fig. 3E and F). We will refer to these mice as
HighTgGSK-3 mice. These mice have been reported to show in-
creased neuronal cell death, particularly in the hippocampus,
and to display Alzheimer’s disease-like biochemical and behav-
ioral alterations (34–36). In summary, the use of this conditional
transgenic mouse system enables the generation of mice with
low or high level of GSK-3 transgenic expression.
To generate R6/1micewith varying levels of transgenic GSK-3
overexpression, we followed the breeding protocol shown in Fig-
ure 3G to set HighTgGSK-3 × R6/1 crossing that renders the six ex-
perimental genotypes relevant for this study: wild-type (WT),
LowTgGSK-3, HighTgGSK-3, R6/1, R6/1 + LowTgGSK-3 and R6/1 +
HighTgGSK-3 mice. A total of 270 mice were generated (Fig. 3G)
that were distributed among the experimental genotypes as fol-
lows:WT (n = 53), LowTgGSK-3 (n = 68), HighTgGSK-3 (n = 47), R6/1
(n = 46), R6/1 + LowTgGSK-3 (n = 39) and R6/1 + HighTgGSK-3 (n =
17). They do not follow a Mendelian segregation of genotypes
(χ2 analysis P = 0) as the percentage of R6/1+HighTgGSK-3 mice
(5.1%) was lower than expected (12.5%) thus indicating that
there is embryonic or perinatal lethality due to the combination
of toxicities associated tomhtt and excess of GSK-3 expression in
R6/1+HighTgGSK-3 mice.
We then veriﬁed by western blot that the decreased GSK-3 le-
vels in striatum of R6/1 mice are progressively corrected by the
low- and high-expression transgenes (Fig. 3H). A similar effect
was observed in the enzymatic activity assay in which the low-
and high-expression transgenes counteract the signiﬁcant de-
crease observed in the striatum of R6/1 mice respect to WT
mice (Fig. 3I).
Low transgenic overexpression of GSK-3 attenuates
brain atrophy in R6/1 mice
As a global indicator of whether modest or high transgenic ex-
pression of GSK-3 would have a positive effect on the progression
of theHDphenotype in R6/1mice, analysis of striatal, cortical and
hippocampal volumewas performed in sagittal sections obtained
from 8-month-old WT, R6/1, R6/1 + LowTgGSK-3 and R6/1 +
HighTgGSK-3 mice by using the Cavalieri method (Fig. 4A and B).
As extensively reported, R6/1 mice presented a reduction in
the volume of these brain regions compared with WT mice
but, interestingly, R6/1 + LowTgGSK-3 mice showed attenuated
atrophy as the volume of cortex (P = 0.0163) and hippocampus
(P = 0.0252) was higher compared with R6/1 mice and a tendency
was also observed in the striatum (Fig. 4A and B). In contrast, no
differences were observed between R6/1 and R6/1 + HighTgGSK-3
mice thus indicating thatmodest GSK-3 overexpression to correct
the inherent decrease in R6/1mice is beneﬁcial but that excessive
GSK-3 production is no longer beneﬁcial probably due to thewell-
documented neuronal toxicity of excessive GSK-3 activity (34,37).
We also analyzed the effect of transgenic GSK-3 expression on
the load of Htt-positive aggregates in R6/1mice. The number and
size of aggregateswere analyzed in striatumof 8-month-old R6/1,
R6/1 + LowTgGSK-3 and R6/1 + HighTgGSK-3 mice by immunos-
taining with an anti-N-terminal-Htt antibody. We found no
changes in the number of striatal inclusions in R6/1 +
LowTgGSK-3 and R6/1 + HighTgGSK-3 mice when compared
with R6/1mice (Fig. 4C and D). However, there is a tendency to in-
crease the size of the inclusions proportional to the increase in
the expression of TgGSK-3 becoming signiﬁcant in R6/1 +
HighTgGSK-3 mice compared with R6/1 mice (Fig. 4D, P = 0.035).
Low transgenic overexpression of GSK-3 attenuates
motor and cognitive deﬁcits in R6/1 mice
We then assessedwhether transgenic GSK-3 expression, particu-
larly the moderate one that was able to correct the brain atrophy
in R6/1 mice, would also attenuate the motor and cognitive HD-
like phenotype of these mice. For this, we ﬁrst analyzed mice of
the six experimental genotypes in the open-ﬁeld test automated
activity cages and found that the hypoactivity observed in R6/1
mice respect to WT mice at 4.5 months of age, as evidenced by
a decrease in ambulatory distance and vertical counts, was im-
proved in R6/1+LowTgGSK-3 and R6/1+HighTgGSK-3 mice during
the exploratory time (0–5 min) but interestingly only R6/1
+lowTgGSK-3 mice showed improved performance during the
5–15 min test time (Fig. 5A and B). Similar results were obtained
when male and female mice were analyzed separately (Supple-
mentary Material, Fig. S4).
The effect of the GSK-3 transgenes was similar in the acceler-
ating rotarod test. Mice were analyzed at 2, 4, 6 and 8 months of
age on the accelerating rotarod (from 4 to 40 rpm) during a 5-min
period, in four trials with 1 h inter-trial periods. As expected, all
mice expressingmhtt showed a deﬁcit in thismotor coordination
task from 4 months of age that progressively worsens until the
late symptomatic age of 8 months (data not shown). Interesting-
ly, when analyzing the latency to fall as a percentage respect to
R6/1 mice, R6/1 + LowTgGSK-3 mice performed signiﬁcantly
Figure 2.Analysis of GSK-3 levels and activity in the striatum, cortex and hippocampus of R6/1mice. (A) Western blot detection of total GSK-3 levels in homogenates from
the striatum, cortex and hippocampus of 3.5-month-old R6/1 and WT mice and from hippocampus of 7.5-month-old R6/1 and WT mice (n = 7–6 for striatum, n = 7–6 for
cortex and n = 7 for hippocampus at 3.5months old and n = 6–7 for hippocampus ofmice at 7.5months old; Student’s t-test; *P < 0.05, **P < 0.01). (B) Quantiﬁcation of GSK-3α
and β levels in A (Student’s t-test; *P < 0.05, **P < 0.01). (C) Quantitative RT-PCR analysis of GSK-3α and GSK-3βmRNA in striatum, cortex and hippocampus of 9-month-old
R6/1mice (n = 5). (D) Western blot detection of total p-Ser-GSK-3 levels in homogenates from striatum, cortex and hippocampus of R6/1 andWTmice at 3.5 months of age
(n = 7 for striatum, n = 7 for cortex and n = 7 for hippocampus; Student’s t-test; **P < 0.01, *P < 0.05). (E) Western blot detection of total p-Ser-GSK-3 levels in homogenates
from striatum, cortex and hippocampus of 7.5-month-old R6/1 and WT mice (n = 7 for striatum, n = 7 for cortex and n = 7 for hippocampus; Student’s t-test; **P < 0.01,
*P < 0.05). (F) Quantiﬁcation of p-Ser-GSK-3α and β levels in D (Student’s t-test; ***P < 0.001, *P < 0.05). (G) Quantiﬁcation of p-Ser-GSK-3α/β levels in (E); (Student’s t-test;
***P < 0.001, **P < 0.01, *P < 0.05). (H and I) In vitro GSK-3 activity assay performed in homogenates of the striatum and cortex (n = 5–7 for striatum and n = 6 for cortex;
Student’s t-test; **P < 0.01) from R6/1 and WT mice at 3.5 months of age (H) and in striatum, cortex and hippocampus at 7.5 months of age (I) (n = 5–6 for striatum,
n = 6–5 for cortex and n = 5 for hippocampus, Student’s t-test; **P < 0.01).
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better than R6/1 and R6/1 + HighTgGSK-3 mice at 2, 4 and 6
months of age (Fig. 5C). Similar results were obtained when
male and femalemice were analyzed separately (Supplementary
Material, Fig. S4).
Finally, we evaluated memory tasks in the six experimental
genotypes in the fear conditioning test. More precisely, we
performed the context dependent fear conditioning that assesses
hippocampal-dependent learning andmemory. Figure 5D shows
representative plots of freezing/activity of mice of the six experi-
mental genotypes, in dark grey the percentage of time that the
mouse spent freezing compared with the percentage of time
that the mouse was moving (light grey). As shown in Figure 5E,
R6/1mice showa clear deﬁcit as their percentage of time freezing
is dramatically lower when compared with WT. This is most
evident in males as it reaches signiﬁcance for males only and
for males + females together but it only shows a tendency for
Figure 3. Generation of R6/1 mice with varying levels of transgenic GSK-3 expression. (A) Diagram showing the structure of the GSK-3 construct used for transgenesis in
LowTgGSK-3. The bidirectional Bi-tetO promoter is followed in one direction by the GSK-3 cDNA sequence, and by the β-galactosidase (β-Gal) sequence with a nuclear
localization signal (NLS) in the other direction. (B) β-Gal immunohistochemistry on sagittal brain sections from 8-month-old LowTgGSK-3 mice in striatum, cortex and
hippocampus. Scale bar corresponds to 20 μm. (C) Double immunoﬂuorescence of β-gal and GSK-3β in hippocampal sections from LowTgGSK-3 mice. Scale bar
corresponds to 20 μm. (D) Schematic representation of the generation of HighTgGSK-3 mice. (E) β-Gal immunohistochemistry on sagittal brain sections from 8-month-
old WT, LowTgGSK-3 and HighTgGSK-3 mice in striatum, cortex and hippocampus. Scale bar corresponds to 20 μm. (F) RT-PCR analysis of transgenic GSK-3β mRNA
and total GSK-3β mRNA in striatum and cortex of LowTgGSK-3 and HighTgGSK-3 respect to WT. (G) Schematic representation of the breeding protocol to obtain R6/1
mice with LowTgGSK-3 or HighTgGSK-3. Number of mice of each of the six experimental genotypes obtained for the whole study is shown as well as the observed
and the expected frequencies. (H) Western blot detection of GSK-3α/β in homogenates from striatum of WT, R6/1, R6/1 + LowTgGSK-3 and R6/1 + HighTgGSK-3 mice
(n = 4; ANOVA, followed by Games–Howell post hoc test; *P < 0.05). (I) In vitro GSK-3 activity assay performed on homogenates of the striatum fromWT (n = 12), R6/1 (n = 13),
R6/1 + LowTgGSK-3 (n = 5) and R6/1 + HighTgGSK-3 (n = 6) mice at 3.5 months of age (ANOVA, followed by Games–Howell post hoc test; *P < 0.05).
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females (Supplementary Material, Fig. S4). Interestingly, this
deﬁcit was attenuated in R6/1 + LowTgGSK-3 mice as they spent
signiﬁcantly more time freezing than R6/1 mice. In summary,
these results demonstrate that a moderate increase in GSK-3
expression is able to attenuate both motor and cognitive deﬁcits
in R6/1 mice.
Discussion
Hereweanalyze for theﬁrst time inHDpostmortembrain the level
and activity of GSK-3 in striatum, the most affected region in this
disease, and we also analyzed other affected brain regions like
cortex and hippocampus. We found a dramatic decrease in GSK-
3 level and activity in striatum and cortex of HDpatients and simi-
lar results were obtained in the R6/1 mouse model. By combining
R6/1micewith our previously generated transgenic mousemodel
with conditional overexpression of GSK-3, we are able to demon-
strate that the mentioned decrease in GSK-3 does contribute to
HD phenotype as the brain atrophy, the locomotor hypoactivity
and the deﬁcits in motor coordination and learning of R6/1 mice
are attenuated by a moderate expression of transgenic GSK-3.
The ﬁrst study of GSK-3 in relation to mhtt toxicity was per-
formed in cellular models expressing the Htt exon 1 fragment
with 74 glutamines (Q74-Htt) (20). The non-selective GSK-3
Figure 4. Forebrain volumetric analysis of R6/1 mice with varying levels of transgenic GSK-3 expression. (A) Representative images of DARPP-32-stained sagittal sections
from WT, R6/1, R6/1 + LowTgGSK-3 and R6/1 + HighTgGSK-3 mice at 8 months of age. (B) The histogram shows the quantiﬁcation of striatal, cortical and hippocampal
volume. Results are expressed as the mean ± SEM. At least four animals per genotype were analyzed. (C–E) EM48 immunohistochemistry to detect striatal mhtt
inclusions. (C) Images showing EM48-positive inclusions in R6/1, R6/1 + LowTgGSK-3 and R6/1 + HighTgGSK-3 mice. (D and E) Histograms showing the number (D) and
size (E) of neuronal intranuclear inclusions (NIIs) in R6/1, R6/1 + LowTgGSK-3 andR6/1 + HighTgGSK-3mice. (ANOVA, followed byDMSmultiple comparisons test; *P < 0.05).
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inhibitor lithium, the selective inhibitor SB216763 and the overex-
pression of a dominant-negative GSK-3 plasmid signiﬁcantly
attenuated Q74-Htt induced cell death. At that time and later, in-
creased GSK-3 levels/activity was reported in Alzheimer’s disease
(6,38–42) and transgenic GSK-3 overexpression in mice had been
shown to cause neurodegeneration (34,35). Accordingly, GSK-3 in-
hibitors were postulated to be neuroprotective inmultiple cellular
and animal models of neurodegeneration (17,43–45). Similarly,
treatment with lithium, alone (22–24,46,47) or in combination
with valproate (25), or with the selective inhibitor AR-A014418
(22) were neuroprotective in invertebrate and rodent models of
HD and of other polyglutamine disorders. In the experiments in
which only lithium was administered, with the exception of the
R6/2mice (24) that did not a showa clear improvement, the chem-
ical rat model of HD (46) and the transgenic SCA1 mouse model
(47) showed an improvement on motor coordination and cogni-
tion. Besides, the invertebrate models also showed attenuated
PolyQ-induced cell death (22,23). However, all these studies were
performed without interrogating whether GSK-3 levels or activity
were increased as a consequence of PolyQ expression.
As mentioned, lithium is a non-selective GSK-3 inhibitor as it
inhibits many other enzymatic activities such as inositol mono-
phosphatase or histone deacetylase 1 (HDAC1) (48,49). Besides,
lithium by itself or in combinationwith other compounds like ra-
pamycin (27) and valproate (25) was found to enhance autophagy
and this has been correlated with its beneﬁcial effect on cell and
animal models of PolyQ toxicity.
Regarding previous ﬁndings about whether GSK-3 activity
changes in response to mhtt expression, an increase in the N-ter-
minal phosphorylated form of GSK-3 was ﬁrst reported in the
STHdhQ111/Q111 striatal cells (50). Since N-terminal phosphorylation
of GSK-3 renders it inactive in some functional scenarios, this was
suggestive of reduced GSK-3 activity. Similar increase in p-GSK-3
was also reported in the striatum of R6/1 (28) and more recently
also in cortex of R6/1 mice (29) and in R6/2 mice (30), although
not in KI140mice (30). However, no direct analysis of GSK-3 activity
had been performed before and only correlation with the level of
phosphorylated substrates has been described. Unfortunately, the
latter does not provide a clear readout of the kinase activity due
to the reported dysregulation in HD of calcineurin (PP2B)
(28,30,51,52) and other phosphatases like PHLPP1 (28) or the other
major ones PP1 and PP2A (30). The latter might also play a promin-
ent role in regulating N-terminal phosphorylation of GSK-3 as it is
decreased in R6/2 mice which show increased N-terminal phos-
phorylation of GSK-3 while it is not altered in KI140 mice which
do not recapitulate the increase in N-terminal phosphorylation of
GSK-3 (30). In summary, the here reported decrease in total GSK-3
levels, increased p-GSK-3 in its inhibitory epitopes and decreased
enzymatic activity is the ﬁrst solid demonstration of decreased
GSK-3 activity in the brain of a mouse model of HD.
Until very recently, therewere no reports on the status of GSK-
3 in HD patients. As mentioned, the analysis of p-Ser-GSK-3 is
hampered by the instability of the epitope and variability with
postmortem interval (33) and only total GSK-3 levels had been ex-
plored in cortex and cerebellum but not in the striatum, themost
affected brain region (29). Accordingly, the here reported analysis
in total GSK-3 levels and enzymatic activity settles that GSK-3 ac-
tivity is indeed decreased in striatum of HD postmortem brain.
In view of these results, GSK-3-related therapies for HD
should not be based on GSK-3 inhibition as initially assumed
but on increasing GSK-3 activity. Since no direct activators of
GSK-3 are available, such activation could be achieved indirectly
by inhibiting kinases such as Akt that are able to phosphorylate
GSK-3 at its inhibitory N-terminal serine residue. In fact, Akt
Figure 5. LowTgGSK-3 expression improves motor tasks and memory tasks in R6/1
mice. (A and B) Open-ﬁeld test of WT (n = 19); LowTgGSK-3 (n = 22); HighTgGSK-3
(n = 13); R6/1 (n = 19); R6/1 + LowTgGSK-3 (n = 17); and R6/1 +HighTgGSK-3 (n = 7) mice
at 4.5 months of age (Kruskal–Wallis, followed by Mann–Whitney U-test; *P < 0.05,
*** P<0.001). (C) Rotarod. Evolution of the mean latency to fall from a rod of mice from
2 to 8 months of age. WT (n = 25); LowTgGSK-3 (n = 52); HighTgGSK-3 (n = 28); R6/1
(n = 30); R6/1 + LowTgGSK-3 (n = 27) and R6/1 +HighTgGSK-3 (n = 12) mice. The
histogram shows the percentage respect to R6/1 of the latency to fall of the R6/
1 + LowTgGSK-3 and R6/1 +HighTgGSK-3 mice (Kruskall Wallis, followed by Mann–
Whitney U-test; **P< 0.01, *P < 0.05). (D and E) Fear conditioning-contextual test.
(D) Representation of the time that the mice spent freezing (dark grey) or not (light
grey) in fear conditioning test. (E) The histogram shows the percentage of freezing in
the fear conditioning-contextual test of WT (n=32); LowTgGSK-3 (n=32); HighTgGSK-3
(n= 22); R6/1 (n= 27); R6/1 +LowTgGSK-3 (n=26) and R6/1 +HighTgGSK-3 (n=10)mice at
5 months (Kruskall–Wallis, followed by Mann–Whitney U-test; ***P< 0.001, *P< 0.05).
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inhibitors are close to clinic for cancer (53). Interestingly, the non-
steroid anti-inﬂammatory drug celecoxib initially developed as a
selective inhibitor of COX-2 is known to also inhibit Akt and this
is believed to contribute to its anti-cancer effect (54) and 2,5-dy-
methyl-elecoxib, a derivative that does not inhibit COX-2 has
been shown therapeutically useful in cancer and in mouse
models of cardiac hypertrophy by inhibiting Akt and thereby
activating GSK-3 (55).
Another angle for therapeutic implications of this workwould
be the identiﬁcation of the mechanism that mediates between
the decrease of GSK-3 activity in HD and the phenotype asso-
ciated with the disease. As it has been described, dominant-
negative GSK-3 transgenic mice develop apoptosis and motor
deﬁcits showing an HD-like phenotype (31). It is known that
this ismediated by an increase of the FasL/Fas signaling pathway
(32,56). Accordingly, reduction of FasL signalingmight be away to
counteract the harmful consequences of decreased GSK-3 activ-
ity in HD. Another GSK-3-associated mechanism might relate to
the efﬁcacy of the transport along microtubules. The latter is
responsible for recruitment of toxic monomeric or oligomeric
mutant proteins into inert inclusion bodies (57). On the other
hand, it has been recently reported an excess of tau in brain of
HD patients and mouse models (58) and excess tau results is a
less efﬁcient transport along microtubules (59) that can be res-
cued by increasing GSK-3 activity (60). This might be the reason
why the size of mhtt inclusions increases in R6/1 mice with
transgenic overexpression of GSK-3. Since this can be protective,
pharmacological interventions able to ease transport along
microtubules might also be beneﬁcial.
In summary, here we demonstrate that GSK-3 levels and ac-
tivity are decreased in the striatum of HD patients as well as in
other affected brain areas. This is mimicked in the R6/1 mouse
model of HD and a moderate increase of GSK-3 in forebrain by
genetic manipulation resulted in attenuation of the HD related
symptoms of the R6/1 mice thus demonstrating that decreased
GSK-3 contributes to HD pathogenesis and offering a new avenue
for therapeutic intervention based on approaches that either
increase GSK-3 activity or attenuate the effects secondary to
the observed GSK-3 decrease.
Materials and Methods
Human brain tissue samples
Brain specimens used in this study from frontal cortex, striatum
and hippocampus of HD subjects and controls were provided by
Institute of Neuropathology (HUB-ICO-IDIBELL) Brain Bank (Hos-
pitalet de LLobregat, Spain), the Neurological Tissue Bank of the
IDIBAPS Biobank (Barcelona, Spain), the Banco de Tejidos Funda-
ción Cien (BT-CIEN, Madrid, Spain) and the Netherlands Brain
Bank (Amsterdam, The Netherlands). Written informed consent
for brain removal after death for diagnostic and research pur-
poses was obtained from brain donors and/or next of kin. Proce-
dures, information and consent forms have been approved by the
Bioethics Subcommittee of Centro Superior de Investigaciones
Cientíﬁcas (Madrid, Spain). The postmortem delay in tissue pro-
cessing was between 1:00 and 23:30 h (Table 1). The neuropatho-
logical examination in HD cases revealed a diagnosis of HD grade
from 0-1 to 4 following the criteria of Vonsattel (61).
Animals
R6/1 mice transgenic for the human exon-1-Htt gene in B6CBAF1
background (62) and GSK-3 overexpression transgenic mice in
the B6 background previously generated (34) were used. All mice
were housed at the Centro de Biología Molecular “Severo Ochoa”
animal facility. Mice were housed four per cage with food and
water available ad libitum and maintained in a temperature-
controlled environment on a 12/12 h light–dark cycle with light
onset at 07:00 h. Animal housing and maintenance protocols fol-
lowed the guidelines of Council of Europe Convention ETS123, re-
cently revised as indicated in the Directive 86/609/EEC. Animal
experiments were performed under protocols (P15/P16/P18/P22)
approved by the Centro de Biología Molecular Severo Ochoa
Table 1. Case information for HD and control cases and experiments






HD 3 M 68 4:00 3
HD n/a F 28 4:15 1, 2, 3
HD 4 F 64 5:00 1
HD 1 M 59 5:05 1
HD 3 M 59 5:30 1, 3
HD 2/3 F 50 5:40 1
HD 3 M 49 5:45 1
HD 3 F 75 6:00 2, 3
HD 2 M 76 6:00 1
HD 2 M 68 6:10 1
HD 3/4 M 55 7:00 3
HD 3 M 53 7:00 3
HD n/a M 62 7:00 2, 3
HD 3 F 72 7:00 3
HD 1 M 73 7:00 1
HD 2 M 71 10:15 1, 3
HD n/a F 47 12:00 2, 3
HD 3 M 60 13:05 1, 2, 3
HD 2 M 72 13:10 1
HD 3 F 65 15:15 1, 3
HD 3 F 72 17:00 1, 3
HD n/a M 44 n/a 2, 3
HD n/a F 69 n/a 2, 3
HD n/a F ND n/a 2, 3
Control – F 57 1:00 2, 3
Control – M 78 2:15 1, 3
Control – F 78 3:40 1, 3
Control – M 56 3:45 1, 2, 3
Control – F 81 4:00 2, 3
Control – F 64 5:00 1, 3
Control – M 85 5:45 1, 3
Control – F 70 6:15 1
Control – M 76 6:45 1
Control – M 55 7:30 1
Control – M 51 7:45 1
Control – M 68 8:00 2, 3
Control – M 60 8:10 1, 3
Control – F 71 8:30 1, 3
Control – M 71 12:00 1, 3
Control – F 60 15:30 1, 2, 3
Control – M 31 17:30 1, 2, 3
Control – M 79 19:00 2, 3
Control – F 81 23:30 1, 3
Control – M 56 n/a 2, 3
Control – F 58 n/a 2, 3
n/a, not available.
1: western blot; 2: qRT-PCR; 3: GSK-3 activity assay. M, male; F, female; PMI,
postmortem interval (h).
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Institutional Animal Care and Utilization Committee (Comité
de Ética de Experimentación Animal del CBM, CEEA-CBM),
Madrid, Spain.
Western blot
The samples from different human brain regions that were stored
at −80°C were ground with amortar in a frozen environment with
liquid nitrogen to prevent thawing of the samples. The resulting
powder was homogenized. For mouse, brains were quickly dis-
sected on an ice-cold plate. Both extracts were prepared by hom-
ogenizing the brain areas in ice-cold extraction buffer consisting
of 20 m HEPES, pH 7.4, 100 m NaCl, 20 m NaF, 1% Triton X-
100, 1 m sodiumorthovanadate, 1 μ okadaic acid, 5 m sodium
pyrophosphate, 30 m β-glycerophosphate, 5 m EDTA and pro-
tease inhibitors (2 m PMSF, 10 µg/ml aprotinin, 10 µg/ml leupep-
tin and 10 µg/ml pepstatin). Samples were homogenized and
centrifuged at 15 000 × g for 15 min at 4°C. The resulting super-
natant was collected, and protein content determined by Bradford
assay. Fifteen micrograms of total protein were electrophoresed
on 10% SDS–PAGE and transferred to a nitrocellulose membrane
and blocked in TBS-T (150 m NaCl, 20 m Tris–HCl, pH 7.5,
0.05% Tween 20) supplemented with 5% non-fat dry milk or 5%
BSA depending on the antibody used. Employed antibodies are:
anti-Gsk-3α/β 1 : 1000 (44–610 form Invitrogen), anti-p-Ser-Gsk-
3α/β 1 : 1000 (9331 fromCell Signaling), anti-p-Tyr-GSK-3α/β 1 : 1000
(44604G from Life Technologies) and anti-β-actin (2228 from
Sigma). The membranes were incubated with the primary anti-
body overnight at 4°C in TBS-T supplemented with 5% non-fat
dried milk or 5% BSA, washed in TBS-T and next incubated with
secondary HRP-conjugated anti-mouse IgG (P0447 from DAKO
Cytomation) on anti-rabbit IgG (P0448 from DAKO Cytomation)
and developed using the ECL detection kit (Perkin Elmer).
Quantitative real-time reverse transcriptase-PCR
Total tissue RNA was extracted from striatum and cortex of HD
and control subjects and from cortex, striatum and hippocampus
of R6/1 and WT mice using the Maxwell® 16 LEV simplyRNA Tis-
sue Kit (Promega). The resulting total RNA (750 ng) was used for
cDNA synthesis with a Super Script III First-Strand Synthesis
SuperMix kit from Invitrogene (PN 11752250) with the ampliﬁca-
tion protocol 30″ at 95°C + (5″ at 95°C + 5″ at 60°C) × 40 + (5″ at 60°C
+ 5″ at 95°C). Quantiﬁcation was performed by real-time PCR
using a CFX 384 System (Bio-Rad) in combination with SsoFast
Eva Green (Bio-Rad), as per manufacturer’s protocol and 1 µl of
primer pair was used. Data were analyzed by GenEx 5.3.7 soft-
ware (Multid AnaLyses AB). The mRNA levels were normalized
ﬁrst relative to total RNA and then relative to the 18S ribosome
subunit for human and the mean of 18S ribosome subunit,
GADPH, β-actin and β-tubulin gene expression for mouse in
each sample. The PCR primers used for human were GSK-3α for-
ward: 5′GTCTCCTACATCTGTTCTCGCTA 3′, GSK-3α reverse: 5′
CAGCCAGCTGACCAAACAT 3′; GSK-3β forward: 5′ GAAAGTATTG
CAGGACAAGAGAT 3′; GSK-3β reverse: 5′ CGGACTATGTTACAG
TGATCTAG 3′. The PCR primers used for mouse were GSK-3α
forward: 5′ GAGCCACAGATTACACCTCGT 3′, GSK-3α reverse: 5′
CTGGCCGAGAAGTAGCTCAG 3′; GSK-3β forward: 5′ GGCAGCAA
GGTAACCACAGT 3′ and GSK-3β reverse: 5′ GATGGCAACCAGT
TCTCCAG 3′. Transgenic GSK-3β forward: (TGCCACCGAGATATC
AAACC), transgenic GSK-3β reverse: (TCGCACAGCTTGAGTAC
AGC), total GSK-3β (that detects endogenous and transgenic
GSK-3) forward: (ATAAAGATGGCAGCAAGG) and total GSK-3β
reverse: (ACCACACCAAATGATCC).
Gsk-3 activity assay
Tissue was homogenized in 20 m HEPES, pH 7.4, 100 m NaCl,
10 m NaF, 1 m VO4Na, 1% Triton X-100, 1 m EDTA, 1 m
EGTA supplemented with a cocktail of protease inhibitors
(Roche). Supernatants were collected after centrifugation at
14 000 × g for 15min. The GS1 peptide (YRRAAVPPSPSLSRHSSPHQ-
S*EDEE) with phosphorylated ser21 was used as substrate (63).
Supernatants were incubated at 37°C with GS1 peptide and [γ-32P]
ATP in 25 m Tris–HCl, pH 7.5, 1 m DTT, 10 mMgCl2 and either
10% DMSO or 100 µm AR-A014418 (selective GSK-3 inhibitor).
The assays were stopped by spotting aliquots on P81 phosphocel-
lulose as described (36). GSK-3 activitywas calculated as the differ-
ence between the activity in the presence of DMSO and the activity
in the presence of AR-A014418.
Immunohistochemistry and immunoﬂuorescence
Mice were sacriﬁced using CO2 and brains immediately removed
and dissected on an ice-cold plate. Left hemispheres were pro-
cessed for histology placed in 4% paraformaldehyde in Sorensen’s
phosphate buffer (PFA) overnight, and then immersed in 30% su-
crose in PBS for 72 h. Once cryoprotected, the samples were in-
cluded in OCT compound (Sakura Finetek Europe), frozen and
stored at −80°C until use. 30 µm sagittal sections were cut on a
cryostat (Thermo Scientiﬁc) and collected and stored free ﬂoating
in glycol containing buffer (30% glycerol, 30% ethylene glycol in
0.02 phosphate buffer) at−20°C. Subsequently, sectionswere im-
mersed in 0.3% H2O2 in PBS for 30 min to quench endogenous per-
oxidase activity. For immunohistochemical staining, sectionswere
blocked for 1 h in PBS containing 0.5% fetal bovine serum, 0.3% Tri-
ton X-100 and 1% BSA (Sigma-Aldrich). Sections were incubated
overnight at 4°C in PBS containing 0.3% Triton X-100 and 1% BSA
with the corresponding primary antibodies: anti-β-galactosidase
1 : 2000 (0855976 from MD Biomedicals) and anti-Huntingtin
clone EM48 1 : 100 (MAB5374 fromMillipore), anti-DARPP32 1 : 1000
(611520 from BD Bioscience) and anti-p-Ser-GSK-3α/β 1 : 200 (9331
from Cell Signaling). Finally, brain sections were incubated in avi-
din–biotin complex using the EliteVectastainkit (Vector Laborator-
ies). Chromogen reactionswere performedwith diaminobenzidine
(SIGMAFASTTM DAB, Sigma) for 10 min. Sectionsweremounted on
glass slides and coverslipped with Mowiol (Calbiochem). Images
were captured using an Olympus BX41 microscope with an Olym-
pus camera DP-70 (Olympus Denmark A/S). For immunoﬂuores-
cence, sections were pretreated with 0.1% Triton X-100 for
15 min, 1 glycine for 30 min and blocking solution (1% BSA and
0.1% Triton X-100) for 1 h. Sections were then incubated overnight
at 4°C with the following primary antibodies in blocking solution:
anti-Gsk-3β 1 : 500 (9315 from Cell Signaling), anti-β-galactosidase
1 : 2000 (z3781 from Promega), anti-p-Ser-GSK-3α/β 1 : 200 (9331
from Cell Signaling), anti-NeuN 1 : 1000 (MAB377 from Millipore)
and anti-GFAP 1 : 500 (60331D from Pharmingen). The following
day, sections were washed in PBS. Then sections were incubated
in avidin–biotin complex using the Elite Vectastain kit (Vector La-
boratories) for 1 h and after that, sectionswere incubatedwith goat
anti-rabbit Alexa 488 (Invitrogen) and goat anti-mouse Alexa 555
(Invitrogen) secondary antibodies for 1 h. Nuclei were counter-
stained with DAPI (Calbiochem). Images were acquired with a
laser confocal LSM710 system coupled to the invert Axioobserver
microscope with a ×63, 1.4 numerical aperture oil immersion
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objective using the Zen2010B sp1 software (Carl Zeiss). Images
were processed using ImageJ 1.45 s.
Stereological quantiﬁcation of brain volume
and huntingtin aggregates
Diaminobenzidine immunohistochemistry was performed as
previously described (64). Tissuewas incubated with the primary
antibodies anti-DARPP32 1 : 1000 (611520 from BD Bioscience) or
anti-EM48 1 : 100 (MAB5374 from Millipore), followed by the
corresponding biotinylated secondary antibody 1 : 200 (Thermo
Fisher). For estimation of cortical, striatal and hippocampal vo-
lumes, 12 sagittal sections per animal spaced 240 μm apart
were examined. Unbiased blinded to genotype counting was per-
formed with Computer-Assisted Stereology Toolbox (CAST) soft-
ware (Olympus Danmark A/S, Ballerup, Denmark). Automated
quantiﬁcation of the number and size of huntingtin aggregates
within the striatum was performed using CellProﬁler v2.8 soft-
ware. Brieﬂy, ﬁve sagittal striatal sections per animal spaced
240 μm apart were chosen for the analysis. Images from the
100% of the striatum were acquired at ×20 magniﬁcation and
EM48 staining was used to identify nuclear inclusions and deli-
mitate their area. The CellProﬁler pipeline ﬁle containing the spe-




Locomotor activity was measured at the age of 4.5 months in
clear plexiglas boxes measuring 43.2× 43.2 cm, outﬁtted with
photobeam detectors for monitoring horizontal and vertical
activity. Activity levels were recorded with an MED Associates’
Activity Monitor (MED Associates, St Albans, VT, USA). Loco-
motor activity data were collected via a PC and was analyzed
with the MED Associates’ Activity Monitor Data Analysis soft-
ware. Mice were placed in a corner of the open-ﬁeld apparatus
and left to move freely. Variables recorded included ambulatory
distance (cm) and vertical counts. Data were individually re-
corded for each animal during 15 min. The number of animals
used for this test was WT, n = 19 (males n = 8, females n = 11);
LowTgGsk-3, n = 22 (males n = 10, females n = 12); HighTgGsk-3,
n = 13 (males n = 3, females n = 10); R6/1, n = 19 (males n = 6,
females n = 13); R6/1 + LowTgGsk-3, n = 17 (males n = 8, females
n = 9); R6/1 + HighTgGsk-3, n = 7 (males n = 2, females n = 5).
Rotarod test
Rotarod testwas performed at the age of 2, 4, 6 and 8months with
accelerating rotarod apparatus (Ugo Basile). Mice were pre-
trained during two days at a constant speed, 4 rpm the ﬁrst day
over 1 min four times or 8 rpm over 1 min four times the second
day. On the third day, rotarod was set to accelerate from 4 to
40 rpm over 5 min andmicewere tested four times. During accel-
erating trials, the latency to fall from the rod was measured.
The number of animals used for this test was: R6/1, n = 35
(males n = 11, females n = 24); R6/1 + LowTgGsk-3, n = 26 (males
n = 12, females n = 14); R6/1 + HighTgGsk-3, n = 12 (males n = 6,
females n = 6).
Contextual fear conditioning test
The test was performed at the age of 5months using the Startfear
1.06 system for fear conditioning from Panlab. During training,
mice stayed in the conditioning chamber for a total of 6 min
30 s. After 2 min of exploration, an 85 dB sound was emitted for
30 s and a 0.2 mA foot-shock was superposed to the tone during
the last 2 s (three times). Thirty seconds after the last foot-shock,
the mouse was removed from the chamber and returned to its
home cage. Twenty-four hours after the conditioning session,
the contextual memory was assessed by introducing the mouse
in the conditioning chamber. The behavioral index use to quan-
tify the memory of context conditioning is freezing, a species-
speciﬁc tonic immobility response. Freezing is deﬁned as a
tonic immobilization, with total absence of movement except
those due to breathing. Freezing scores were assessed during
6 min, no tone or foot-shock being presented to the animal
during this test. The number of animals used for this test was:
WT, n = 32 (males n = 5, females n = 27); LowTgGsk-3, n = 32
(males n = 19, females n = 13); HighTgGsk-3, n = 22 (males n = 5,
females n = 17); R6/1, n = 27 (males n = 8, females n = 19); R6/1 +
LowTgGsk-3, n = 26 (males n = 12, females n = 14); R6/1 +
HighTgGsk-3, n = 10 (males n = 6, females n = 4).
Data analysis
Statistical analysis was performedwith SPSS 19.0 (SPSS® Statistic
IBM®). Data are represented as means ± SEM. The normality of
the data was analyzed by Shapiro-Wilk test. For two-group com-
parison, two tail Student’s t-test (data with normal distribution)
or Mann–Whitney U-test (data with non-normal distribution)
was performed. For multiple comparisons, data with a normal
distribution were analyzed by one-way ANOVA test followed by
a DMS or a Games–Howell post hoc test. Statistical signiﬁcance
of non-parametric data was determined by Kruskal–Wallis test
when analyzing all experimental groups followed by a Mann–
Whitney U-test for analysis of paired genotypes. A critical value
for signiﬁcance of P < 0.05 was used throughout the study.
Supplementary Material
Supplementary Material is available at HMG online.
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